stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) EV/FCF
As of 5 November 2026, Zai Lab Limited Unsponsored ADR (ZLAB) trades at a EV/FCF of −10.5×. Over the past ten years it has ranged from −60.5× (January 2021) to 2.1× (June 2018); the current reading is higher than 33% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −8.2× | — |
| FY2024 | −6.7× | — |
| FY2023 | −8.9× | — |
| FY2022 | −5.0× | — |
| FY2021 | −7.8× | — |
| FY2020 | −41.2× | — |
| FY2019 | −10.3× | — |
| FY2018 | 1.3× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −12.6× | — |
| Jun 2026 | −10.1× | — |
| Mar 2026 | −11.6× | — |
| Dec 2025 | −8.2× | — |
| 27 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MBX MBX Biosciences, Inc. compare | −22.3× |
| NAMS NewAmsterdam Pharma Company N.V. compare | −11.4× |
| XNCR Xencor, Inc. compare | −10.8× |
| ZLAB Zai Lab Limited Unsponsored ADR | −10.5× |
| PHVS Pharvaris N.V. compare | −10.5× |
| CLDX Celldex Therapeutics, Inc. compare | −6.2× |
| RXRX Recursion Pharmaceuticals, Inc. compare | −4.3× |
| RCUS Arcus Biosciences, Inc. compare | −3.7× |
| ADMA ADMA Biologics Inc compare | 25.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement